LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Listă Acțiuni・Merck & Co Inc.

Merck & Co Inc.

Închisă

SectorSănătate

112.58 1.16

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

110.97

Maxim

112.86

Indicatori cheie
By Trading Economics
Venit	-7.2B -4.2B
Vânzări	-114M 16B
P/E Medie Sector	31.347 51.415
EPS	-1.28
Randament dividend	2.94
Marjă de profit	-26.053
Angajați	73,000
EBITDA	-6.2B -1.9B

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+21.75% upside

Dividende
By Dow Jones
Randament dividend Medie Sector	2.94% 2.34%
Următoarele câștiguri	4 aug. 2026
Data viitoare de dividende	7 iul. 2026
Următoarea dată ex-dividende	15 iun. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	2.6B 275B
Deschiderea anterioară	111.42
Închiderea anterioară	112.58

Sentimentul știrilor

By Acuity

54%

46%

249 / 345 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

76.03 / 83.28 Suport & Rezistență

Merck & Co Inc. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

30 apr. 2026, 14:20 UTC

Câștiguri

Merck 1Q Sales Rise on Continued Keytruda Growth -- Update

30 apr. 2026, 10:45 UTC

Câștiguri

Merck 1Q Sales Rise on Continued Keytruda Growth

5 mai 2026, 18:12 UTC

Câștiguri

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 mai 2026, 13:54 UTC

Câștiguri

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 mai 2026, 12:48 UTC

Achiziții, Fuziuni, Preluări

Merck Cites Costs Associated With Advancing TERN-701 and Financing >MRK

5 mai 2026, 12:48 UTC

Achiziții, Fuziuni, Preluări

Merck: GAAP and Adj EPS Expected to Be Negatively Impacted by About 12c/Shr in 2026 >MRK

5 mai 2026, 12:47 UTC

Achiziții, Fuziuni, Preluări

Merck: Transaction Expected to Be Accounted for as Asset Acquisition, Resulting in Chg of About $5.8 B, or $2.35/Shr, Included in 2Q and FY26 Results >MRK

5 mai 2026, 12:45 UTC

Achiziții, Fuziuni, Preluări

Merck Completes Acquisition Of Terns Pharmaceuticals, Inc. >MRK TERN

1 mai 2026, 18:35 UTC

Câștiguri

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 mai 2026, 14:53 UTC

Câștiguri

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

30 apr. 2026, 13:27 UTC

Câștiguri

Merck Stock Falls After Earnings. It's Working on Ways to Blunt Future Lost Keytruda Sales. -- Barrons.com

30 apr. 2026, 10:47 UTC

Câștiguri

Update: Merck Stock Rises on Earnings. These Problems Loom Larger Than Keytruda Patent Cliff. -- Barrons.com

30 apr. 2026, 10:30 UTC

Câștiguri

Merck: Also Anticipate EPS Will Be Negatively Affected by About 12c Over Remainder of 2026 Following Close of Terns Deal >MRK

30 apr. 2026, 10:30 UTC

Câștiguri

Merck Raises 2026 View To Adj EPS $5.04-Adj EPS $5.16 Vs Prior View $5-$5.15 >MRK

30 apr. 2026, 10:30 UTC

Câștiguri

Merck: 2026 Outlook Doesn't Reflect Any Impact From Proposed Acquisition of Terns Pharmaceuticals, Which Is Expected to Close in May and Result in One-Time Charge of About $2.35/Shr >MRK

30 apr. 2026, 10:30 UTC

Câștiguri

Merck: Sales Outlook Includes Positive Impact From Forex of About 1% at Mid-April 2026 Exchange Rates >MRK

30 apr. 2026, 10:30 UTC

Câștiguri

Merck: Adj EPS Outlook Also Reflects One-Time Charge of $3.62/Shr for Acquisition of Cidara >MRK

30 apr. 2026, 10:30 UTC

Câștiguri

Merck: Adj EPS Outlook Includes Positive Impact From Forex of About 10c/Shr at Mid-April 2026 Exchange Rates >MRK

30 apr. 2026, 10:30 UTC

Câștiguri

Merck Narrows 2026 View To Sales $65.8B-$67B Vs Prior View $65.5B-$67B >MRK

30 apr. 2026, 10:30 UTC

Câștiguri

Merck: Latest 1Q Includes Charge of $3.62/Share for the Acquisition of Cidara >MRK

30 apr. 2026, 10:30 UTC

Câștiguri

Merck: 1Q Gardasil/Gardasil 9 Sales Also Reflect Lower Sales in U.S. Primarily Due to Unfavorable Public-Sector Purchasing Patterns, Partially Offset by Higher Net Pricing >MRK

30 apr. 2026, 10:30 UTC

Câștiguri

Merck 1Q Gardasil/Gardasil 9 Sales Down 19% >MRK

30 apr. 2026, 10:30 UTC

Câștiguri

Merck: Lower 1Q Januvia/Janumet Sales Due to Lower Demand and Net Pricing in U.S., Lower Demand in China and Most Other International Markets Due to Generic Competition >MRK

30 apr. 2026, 10:30 UTC

Câștiguri

Merck: Pleased With Progress and Excited for What's Ahead, as We Enter Particularly Robust Period of Phase 3 Data Readouts and Deliver on Promise of Our Pipeline for Patients >MRK

30 apr. 2026, 10:30 UTC

Câștiguri

Merck 1Q Winrevair Sales $525M, Up 88%, Reflecting Continued Uptake in U.S. and Early Launch Uptake in Certain Intl Mkts, Especially Japan and Europe >MRK

30 apr. 2026, 10:30 UTC

Câștiguri

Merck: 1Q Animal Health Sales Growth Attributable to Performance in Both Livestock and Companion Animal Product Portfolios >MRK

30 apr. 2026, 10:30 UTC

Câștiguri

Merck: Lower 1Q Gardasil/Gardasil 9 Sales Primarily Due to Lower Demand in China as Well as Lower Sales in Japan Following National Catch-Up Immunization Program >MRK

30 apr. 2026, 10:30 UTC

Câștiguri

Merck 1Q Pharmaceutical Sales Up 5% >MRK

30 apr. 2026, 10:30 UTC

Câștiguri

Merck 1Q Animal Health Sales Up 13% >MRK

30 apr. 2026, 10:30 UTC

Câștiguri

Merck 1Q Sales $16.29B >MRK

Comparație

Modificare preț

Merck & Co Inc. Așteptări

Obiectiv de preț

By TipRanks

21.75% sus

Prognoză pe 12 luni

Medie 135.61 USD 21.75%

Maxim 179 USD

Minim 112 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMerck & Co Inc. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

20 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 20 analiști care au acordat evaluări ale acțiunilor Merck & Co Inc. - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

76.03 / 83.28Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

249 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.